These radiopharmaceuticals have shown impressive results in targeted radionuclide therapy, with metastatic castration-resistant prostate cancer patients experiencing significant declines in prostate-specific antigen (PSA) levels and improved quality of life. Here, KLK3 is linked to prostate carcinoma.